Frank Reed

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

Boston's Weiss Asset Management reveals a strategic 4.17% derivative stake in International Personal Finance as a takeover deadline looms.

A hedge fund's disclosure reveals a puzzling short position and a fresh stock purchase in American Axle, hinting at a high-stakes arbitrage play.

Weiss Asset Management builds a major stake in International Personal Finance using only derivatives, signaling a new era of high-stakes M&A battles.

A $2.4B deal for Alphawave IP and a revealing investor filing pull back the curtain on the high-stakes race to build the infrastructure for an AI world.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

A major hedge fund's move in a $2.4B semiconductor deal reveals a critical truth: the future of precision medicine is built on high-speed data infrastructure.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.

A $2.4B semiconductor deal seems distant from medicine, but it's forging the AI hardware backbone for the next generation of precision health.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

A mandatory filing reveals hedge fund Balyasny's 1.26% CFD stake in Just Group, offering a rare glimpse into high-stakes M&A strategy and regulation.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

A regulatory filing from Weiss Asset Management reveals a complex arbitrage play on Alphawave IP, spotlighting its critical role in the Qualcomm deal.

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

A 1.26% stake in Just Group, held via derivatives by Balyasny, reveals a classic merger arbitrage strategy as Brookfield's £2.4bn acquisition nears.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.